Sentinel Trust Co. LBA Has $3.10 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 12th, 2023

Sentinel Trust Co. LBA increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 316.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,022 shares of the company’s stock after buying an additional 15,216 shares during the period. Sentinel Trust Co. LBA’s holdings in Johnson & Johnson were worth $3,103,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Geode Capital Management LLC increased its stake in shares of Johnson & Johnson by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock valued at $8,456,643,000 after acquiring an additional 294,671 shares in the last quarter. Morgan Stanley increased its stake in shares of Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after acquiring an additional 4,521,062 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Johnson & Johnson by 15.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after acquiring an additional 3,849,148 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $4,609,399,000. 67.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

JNJ has been the subject of several research analyst reports. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Citigroup began coverage on shares of Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 price target for the company. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Atlantic Securities boosted their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Finally, Barclays boosted their price target on shares of Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research note on Monday, July 24th. Eight analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $171.80.

Read Our Latest Stock Report on JNJ

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 47,163 shares of company stock valued at $7,928,856. 0.20% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $173.85 on Friday. The company has a fifty day moving average price of $164.56 and a 200-day moving average price of $161.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The firm has a market cap of $451.83 billion, a price-to-earnings ratio of 35.19, a PEG ratio of 2.90 and a beta of 0.54. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.59 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.75 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 96.36%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.